Navigation Links
Stryker Declares a $0.18 Per Share Quarterly Dividend
Date:2/9/2011

KALAMAZOO, Mich., Feb. 9, 2011 /PRNewswire/ -- Stryker Corporation (NYSE: SYK) announced today that its Board of Directors has declared a quarterly dividend of $0.18 per share payable on April 29, 2011, to shareholders of record at the close of business on March 31, 2011.

The quarterly dividend payment represents a 20% increase versus the prior year and is consistent with Stryker's commitment to leveraging its balance sheet and strong cash flow generation to maximize shareholder value. The dividend increase, combined with the previously authorized $500 million share repurchase program, reflects Stryker's multi-pronged cash deployment strategy, which also includes making the necessary investments that will drive continued sales and earnings growth.

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care.   The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives.  For more information about Stryker, please visit www.stryker.com.


'/>"/>
SOURCE Stryker Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
2. Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010
3. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
4. TriMed, Inc. Announces Licensing Agreement with Stryker
5. Stryker Increases Expected 2010 Results and Provides 2011 Outlook
6. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
7. Stryker to Present at Investor Conferences
8. Stryker Announces Election of New Director
9. Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend
10. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
11. Medtronic, Stryker, and BrainLAB Covered in New Surgical Navigation Market Research Reports Released by Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... announces the release of its newest report, Capitalizing ... a sluggish economy and cuts being made to laboratory budgets, ... increase substantially over the next several years to $688.9 M ... of 2011. Suppliers of stem cell related products are ...
... (Nasdaq: TSPT ), a specialty pharmaceutical company ... that address important therapeutic needs in the field of ... first quarter 2009 on Wednesday, May 13, 2009, after ... begin at 5:00 p.m. ET (2:00 p.m. PT) on ...
Cached Medicine Technology:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 2BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available 3Transcept Pharmaceuticals to Report First Quarter 2009 Results 2Transcept Pharmaceuticals to Report First Quarter 2009 Results 3
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... Million- Annual Basic and Diluted Net Loss per Share of ... Share, or $4.77 per Diluted ShareSILVER SPRING, Md., Feb. 17 ... announced its financial results for the fourth quarter and year ... revenues for 2008 grew in excess of 30% for the ...
... Bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update today ... Neuradiab(R) in the most advanced form of brain ... of Directors has recommended a review of strategic ... new projections of site initiation and patient enrollment ...
... Feb. 17 The Alliance for National Defense ... Defense to update or eliminate rules excluding servicewomen ... parental leave policies.The alliance is a non-profit organization ... military women. AND encourages and promotes the ...
... OSAKA, Japan and FLORHAM PARK, N.J., Feb. 17 ... year-long studies of velneperit, a novel neuropeptide Y (NPY) ... their primary endpoint of demonstrating a statistically significant reduction ... the potential for the NPY Y5 receptor as a ...
... solution for early detection of ear infectionsLENEXA, Kan., Feb. ... and tweeting away this winter on the topic of ... children,s visits to the emergency room."Parents often turn to ... infections," says Joe Kessinger of Innovia Medical, manufacturer of ...
... Host Quarterly Analyst Briefing on Thursday, 26 February ... at Frost & Sullivan is pleased ... on Medical Trends Impacting the Chemicals and Materials ... 2009 at 3 p.m. GMT.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ...
Cached Medicine News:Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 2Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 4Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 5Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 6Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 7Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 8Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 9Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 10Health News:Bradmer provides clinical trial update and announces evaluation of strategic alternatives 2Health News:Bradmer provides clinical trial update and announces evaluation of strategic alternatives 3Health News:Bradmer provides clinical trial update and announces evaluation of strategic alternatives 4Health News:AND Calls on DoD to Open All Military Units to Women, Grant Parental Leave to Service Members 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 3Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 4Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 5Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 6Health News:Video: Ear Infections Spark Online Conversations Among Concerned Parents 2Health News:Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets 2Health News:Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets 3
... Every Bard® Biopsy Instrument and Needle is ... important goal: a large quality, reliable core ... performance, featuring ultra-sharp tips and polished surfaces ... selection of biopsy systems and needle sizes ...
... Used to obtain multiple core biopsies ... Quick-Core® Biopsy Needle design facilitates one-handed control. ... tissue sample. Beveled point stylet permits easy ... to surrounding tissue. Sharp cutting edge of ...
... Q-Track i Holter Monitoring System uses technology ... the worlds first true 12-lead digital Holter ... of any beat contained in the 24-hour ... ,The preprocessing work done by the Q-12 ...
... incorporates the iQ®200 Automated Urine Microscopy ... AX-4280 Automated Urine Chemistry Analyzer (AX-4280) ... and microscopic analysis. The iQ200 uses ... neural network, to classify and quantitate ...
Medicine Products: